Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

REPLBullishIndustry Newsnews

High materiality7/10

FDA panel reviews RP1 BLA; August 2026 action date could unlock approval

Jul 31, 2026, 10:32 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory catalysts can drive outsized moves; current article notes a large intraday rally and a clear near-term timeline, but outcomes remain uncertain given prior data concerns.

AI summary

What happened, with direct paths to the underlying reporting

REPL's RP1 BLA, for combination with nivolumab in advanced melanoma, is under FDA review with an August 2, 2026 Class 1 resubmission action date. Prior concerns include a 2025 Complete Response Letter and staff notes that the data may be not interpretable. The initial market move was a sharp rally, underscoring regulatory risk and potential upside on clearance.

FDA panel reviews RP1 BLA for advanced melanoma with nivolumab; action date Aug 2, 2026.
FDA staff called mid-stage data not interpretable; June 2025 CRL cited inadequacy.
ASCO 2026 data highlighted long-term survival; Capricor vote went the other way.
REPL shares up ~104% on news; market reaction to regulatory proceedings.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

FDA panel reviews RP1 BLA; August 2026 action date could unlock approval

FDA approval of Replimune drug marks first marketed product after setbacks

REPL Faces Securities Probe Following FDA RP1 Concerns, Shares Slump

FDA Efficacy Concerns for Replimune Skin Cancer Drug Ahead of July 30 Meeting

FDA to resubmit REPL's skin cancer drug after two rejections signals regulatory persistence